Blisibimod Misses PEARL-SC Endpoint; Anthera Plummets
Shares of Anthera Pharmaceuticals Inc. struggled to find a floor Thursday after the company reported following the market's close Wednesday afternoon that its Phase IIb PEARL-SC study of blisibimod in systemic lupus erythematosus (SLE) failed to meet the primary efficacy endpoint – clinical improvement at 24 weeks in the SLE responder index for the pooled blisibimod dose groups – due to lack of efficacy in two low-dose groups.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST